Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention.

Atherosclerosis - 1 Apr 2024

Gagnon Eloi, Arsenault Benoit J

Abstract excerpt

BACKGROUND AND AIMS: Inhibitors of apolipoprotein C-III (apoC3) are currently approved for the reduction of triglyceride levels in patients with Familial Chylomicronemia Syndrome. We used drug target Mendelian randomization (MR) to assess the effect of genetically predicted decrease in apoC3 blood protein levels on cardiometabolic traits and diseases. METHODS: We quantified lifelong reductions in apoC3 blood...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Apolipoprotein C-III
Share to Blood Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiovascular Diseases

Share to Cholesterol, LDL

Share to Coronary Artery Disease

Share to Pancreatitis

Share to Triglycerides

Source

Identifiers

PMID: 38547584
DOI: 10.1016/j.atherosclerosis.2024.117501

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases prevention.PMID 38547584Read ↗

Drug target Mendelian randomization supports apolipoprotein C3-lowering for lipoprotein-lipid levels reductions and cardiovascular diseases preventionSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Drug-target Mendelian randomization analysis supports lowering plasma ANGPTL3, ANGPTL4, and APOC3 levels as strategies for reducing cardiovascular disease riskSemantic proximity Read ↗

Joint Associations of APOC3 and LDL-C-Lowering Variants With the Risk of Coronary Heart Disease.Semantic proximity Read ↗

LDL-C and TC Mediate the Risk of PNPLA3 Inhibition in Cardiovascular DiseasesSemantic proximity Read ↗

Genetic inhibition of angiopoietin-like protein-3, lipoprotein-lipid levels and cardiometabolic diseasesSemantic proximity Read ↗

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic riskSemantic proximity Read ↗

Metabolomic signatures of lipid-modifying therapies using drug target Mendelian randomizationSemantic proximity Read ↗

Lipid-Related Genetic Variants for Personalized Dietary Interventions: A Systematic Review.Semantic proximity Read ↗

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisationSemantic proximity Read ↗

Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.Semantic proximity Read ↗

APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.